logo
The six biggest make-up mistakes that are making your face look cakey in hot weather, according to a top beauty expert

The six biggest make-up mistakes that are making your face look cakey in hot weather, according to a top beauty expert

Daily Mail​18-07-2025
Sweaty skin, cakey cheeks, smudgy under-eyes: we all know the pains of trying to apply make-up in hot weather. You'll leave the house looking perfectly glam, and after an hour of travelling and standing in the sun, find your face resembles a half-melted wax figure from Madame Tussauds.
If you can relate, it's likely you're making a few common make-up mishaps. Don't feel bad, we were too – at least until we spoke to Saffron Hughes, professional MUA at FalseEyelashes.co.uk.
Hughes set us straight by highlighting the six biggest errors people make when it comes to heatwave make-up, and her top tips on how to avoid them. From piling on the powder to skipping setting spray, here are the mistakes to avoid if you want to stay looking hot in the heat.
Using the wrong type of primer
Primers are one of the least understood make-up products, and many people think wearing any – regardless of skin type and formula – is good enough. But, as Hughes points out, some primers are actually detrimental to make-up's staying power when it's warm outside.
'Oil-based primers can make your make-up feel like it's sliding off by lunchtime,' Hughes says. 'They're often too rich for warm weather, and can actually leave your skin looking shinier than intended.'
'I always recommend a silicone-based primer in the summer. It grips your make-up better and gives a smoother, more matte finish – especially when sweaty skin is producing more oil anyway. If you know your skin suits oil-based primers, opt for a lightweight formula that won't make your face look greasier.'
Overlooking waterproof formulas
We know it seems extra to have a 'summer' and 'winter' foundation, but the truth is it's worth investing in a longer-lasting waterproof formula that works harder when it's hot.
'Regular foundation might look fine in the morning, but once the heat kicks in, it can start to break down fast,' Hughes says. 'You really want to look for long-wear or waterproof on the label.
'These formulas are built to last through sweat, humidity, and the works. It sounds obvious, but a lot of people skip this step and end up wondering why their base has disappeared by midday.'
It's not just your foundation that needs a change-up. 'The same goes for investing in waterproof eye products,' Hughes advises. 'If you're going to be out for hours, especially in the sun, your make-up needs to hold up without constant touch-ups.'
Applying your base in one layer
We're all guilty of slathering foundation on with our hands, usually when we're running late for work and can't locate a clean brush. But according to Hughes, it's one of the simplest reasons your make-up has zero staying power.
'Piling on product rarely works well in warm weather,' Hughes explains. 'It's much better to apply your foundation in thin layers and build gradually, using a damp beauty sponge. Let each layer set before adding more. That way, you avoid caking and help your make-up last without separating or settling.'
'This approach also allows your skin to breathe, which is key to avoiding that heavy, 'melted' look later in the day.'
Overdoing it with powder
'A bit of translucent or setting powder is essential in summer,' Hughes says, 'as it helps absorb oil and keeps your make-up in place.'
But use too much product and it can quickly backfire. 'Powder tends to cling to sweat or settle into fine lines,' Hughes says, 'especially in the sun, which can leave your skin looking cakey or textured.'
So how can you remedy that weird cakey look that comes with too much powder? Hughes recommends using a light hand and focusing on the T-zone. 'Apply with a small fluffy brush rather than a puff or sponge,' she says, 'and only where you actually need it.'
Skipping setting spray
Lots of us imagine setting spray is an unnecessary cost – after all, if we've already spent extra on waterproof formulas, what's the need? But ask any good MUA like Hughes, and they'll tell you in the summer months, it's one of the most important products in your make-up bag.
'A good setting spray works like a veil,' Hughes says, 'helping to keep products in place even when your skin starts to warm up. Some formulas even help to cool and refresh the skin, which can make a huge difference on a hot day.'
'Look for sprays that specifically mention staying power or sweat-resistance, and let it dry naturally after spritzing.'
Sticking to your usual mascara and eyeliner
We know it's expensive to seasonally swap out your make-up items. But according to Hughes: 'Non-waterproof mascara and eyeliner just don't hold up in summer, especially if you're sweating or spending time outside. They're far more likely to smudge or transfer, which can undo your whole eye look.'
She suggests switching to waterproof formulas during warmer months and, for added staying power, layering products. 'I often recommend applying false lashes using a strong lash adhesive for extra definition. It gives a cleaner finish and holds much better in the heat.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

First new treatment for advanced bladder cancer in decades given green light
First new treatment for advanced bladder cancer in decades given green light

The Independent

time28 minutes ago

  • The Independent

First new treatment for advanced bladder cancer in decades given green light

A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.

New advanced bladder cancer treatment can ‘double chances of survival'
New advanced bladder cancer treatment can ‘double chances of survival'

The Independent

timean hour ago

  • The Independent

New advanced bladder cancer treatment can ‘double chances of survival'

A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, experts say the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease. They said there had been real 'unmet need' for patients with advanced disease, with some 29 per cent of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30 per cent) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5 per cent of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.

Hundreds with rare conditions to benefit from new blood matching test
Hundreds with rare conditions to benefit from new blood matching test

The Independent

timean hour ago

  • The Independent

Hundreds with rare conditions to benefit from new blood matching test

A new personalised ' blood matching' test has been launched for people with rare conditions who require regular blood transfusions. The move will allow donor blood to be matched to these patients more closely, to reduce the risk of severe reactions. It is the first time it has been used for patients with rare inherited anaemias – with around 300 people eligible for testing, according to NHS Blood and Transplant (NHSBT). The new test uses genetics to generate detailed blood group information. The programme has been backed by the family of toddler Woody Mayers, aged 22 months, who has a rare inherited anaemia called congenital dyserythropoietic anaemia (CDA) type 1. The condition causes the bone marrow to struggle to produce healthy red blood cells, which carry oxygen around the body. It is estimated to affect between one to five out of every million babies. Patients have low haemoglobin levels, meaning Woody relies on blood transfusions every four weeks to stay alive. However, the donor blood must be carefully matched to reduce the risk of patient's developing antibodies against certain blood types, which can cause severe reactions and make transfusions more difficult in the future. The new genotyping testing programme, a partnership between NHSBT and NHS England, uses genetics to identify more of the rarer blood groups. Samples are collected at routine hospital appointments, with patients' DNA tested to find out their blood types. About 300 people with transfusion dependent, rare inherited anaemias, are eligible for the test. All patients with sickle cell disorder and thalassaemia are also eligible, even if they do not rely on blood transfusions. Kate Downes, head of genomics at NHSBT, said: 'The new genotyping test can test blood groups faster and more extensively than standard testing methods.' Professor Dame Sue Hill, chief scientific officer at NHS England, said: 'The power of genomics is transforming medicine, with extended blood group genotyping now being utilised to help patients, especially those requiring regular transfusions. 'This is an exceptional example of an evidence-based innovation, developed from genetic data, being used to drive forward improvements that will make a huge difference across the NHS. 'Blood donations can be lifesaving for patients, and the NHS needs a constant flow of donations to provide people with the best possible care, so I'd encourage anyone who can donate to do so.' Woody's family were alerted to potential health conditions at a 20-week pregnancy scan. He was born prematurely at 34 weeks with haemoglobin levels around a quarter of what they should have been. Woody's mother Polly Mayers, 35, from Robertsbridge in East Sussex, said: 'When he was born, he was very poorly and pale. He didn't cry for a few minutes. He needed ventilation breaths. It was really frightening. 'The first few days were very critical for Woody. He was extremely unwell. Nobody knew the cause for his haemolytic anaemia.' The toddler has now being having regular transfusions fore more than a year, receiving 140mls of red blood cells every four weeks to boost his haemoglobin. Despite this, his family describes him as an energetic little boys who likes trips to the park and riding his bike. His mother added: 'Woody will need the blood to be well-matched so that his transfusions don't become too difficult or risky. 'The test will help him and anyone else with a similar condition. I hope everyone eligible gets it.' Ms Downes said: 'Woody has very rare disorder and he relies on blood transfusions to stay alive but these need to be well matched. 'We want everyone eligible, like Woody, to be tested so they can get better matched blood. We also need more people to donate, so we can supply the matched lifesaving blood to Woody and people like him.' Woody's family are also urging people to donate blood. Mrs Mayers, a community matron, said: 'There's no way to sugar-coat it – if it wasn't for blood donors, Woody would not be alive. 'I'm incredibly grateful to blood donors for ensuring blood is available when he needs it.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store